Heron Therapeutics (HRTX) Short Interest Ratio & Short Volume $1.32 +0.02 (+1.54%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$1.36 +0.04 (+3.03%) As of 08:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Heron Therapeutics Short Interest DataHeron Therapeutics (HRTX) has a short interest of 32.96 million shares. This marks a 1.76% increase in short interest from the previous month. The short interest ratio (days to cover) is 19.3, indicating that it would take 19.3 days of the average trading volume of 1.66 million shares to cover all short positions.Current Short Interest32,960,000 sharesPrevious Short Interest32,390,000 sharesChange Vs. Previous Month+1.76%Dollar Volume Sold Short$40.87 millionShort Interest Ratio19.3 Days to CoverLast Record DateSeptember 15, 2025Outstanding Shares183,315,000 sharesPercentage of Shares Shorted17.98%Today's Trading Volume2,155,400 sharesAverage Trading Volume1,664,812 sharesToday's Volume Vs. Average129% Short Selling Heron Therapeutics? Sign up to receive the latest short interest report for Heron Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartHRTX Short Interest Over TimeHRTX Days to Cover Over TimeHRTX Percentage of Float Shorted Over Time Heron Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 9/15/202532,960,000 shares $40.87 million +1.8%N/A19.3 $1.24 8/31/202532,390,000 shares $43.73 million -2.5%22.4%19.5 $1.35 8/15/202533,230,000 shares $44.20 million -5.8%N/A20.3 $1.33 7/31/202535,260,000 shares $61.00 million -0.2%24.4%22.7 $1.73 7/15/202535,320,000 shares $72.05 million -4.3%N/A23.1 $2.04 6/30/202536,920,000 shares $76.42 million +7.9%25.7%23.4 $2.07 6/15/202534,210,000 shares $66.03 million +0.7%23.8%23.4 $1.93 5/31/202533,960,000 shares $64.18 million -1.3%23.7%22.3 $1.89 5/15/202534,410,000 shares $64.35 million +3.3%24.0%17.6 $1.87 4/30/202533,300,000 shares $80.59 million +1.0%N/A17.9 $2.42 Get the Latest News and Ratings for HRTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 4/15/202532,960,000 shares $63.28 million +1.4%23.0%19.9 $1.92 3/31/202532,520,000 shares $71.54 million +1.4%22.7%18.8 $2.20 3/15/202532,070,000 shares $74.40 million +2.4%22.4%17.5 $2.32 2/28/202531,330,000 shares $77.39 million +1.8%21.9%10.2 $2.47 2/15/202530,770,000 shares $54.77 million -0.2%21.5%10.7 $1.78 1/31/202530,840,000 shares $52.43 million -0.7%N/A10 $1.70 1/15/202531,060,000 shares $47.21 million +1.1%N/A10 $1.52 12/31/202430,710,000 shares $46.99 million +2.4%N/A9.9 $1.53 12/15/202429,980,000 shares $47.97 million +8.9%N/A9.6 $1.60 11/30/202427,540,000 shares $32.77 million -1.3%N/A8.8 $1.19 11/15/202427,910,000 shares $33.21 million -3.1%N/A15.3 $1.19 10/31/202428,810,000 shares $50.13 million -6.0%N/A15.7 $1.74 10/15/202430,640,000 shares $55.15 million -3.3%N/A14.9 $1.80 9/30/202431,700,000 shares $63.08 million -10.6%N/A14.4 $1.99 9/15/202435,440,000 shares $66.27 million -1.3%N/A14.9 $1.87 8/31/202435,920,000 shares $69.33 million -0.1%N/A15.5 $1.93 8/15/202435,960,000 shares $70.12 million +0.9%N/A14.9 $1.95 7/31/202435,630,000 shares $105.82 million -0.1%N/A14.9 $2.97 7/15/202435,660,000 shares $118.03 million +8.7%N/A14.7 $3.31 6/30/202432,820,000 shares $114.87 million +7.7%N/A14 $3.50 6/15/202430,470,000 shares $109.69 million +1.4%N/A14.5 $3.60 5/31/202430,040,000 shares $111.15 million -0.8%N/A12.3 $3.70 5/15/202430,270,000 shares $90.81 million +10.9%N/A12.6 $3.00 4/30/202427,290,000 shares $63.31 million +7.3%N/A11.6 $2.32 4/15/202425,430,000 shares $75.02 million -0.5%N/A9.8 $2.95 3/31/202425,550,000 shares $70.77 million +0.5%N/A8.8 $2.77 3/15/202425,430,000 shares $77.82 million +3.7%N/A8.4 $3.06 2/29/202424,530,000 shares $65.25 million -0.4%N/A8.8 $2.66 2/15/202424,620,000 shares $70.91 million +1.2%N/A8.4 $2.88 1/31/202424,330,000 shares $58.64 million +13.1%N/A6.6 $2.41 1/15/202421,520,000 shares $46.27 million +6.5%N/A6.5 $2.15 12/31/202320,210,000 shares $34.36 million -3.8%N/A6 $1.70 12/15/202321,000,000 shares $38.01 million -2.7%N/A6.8 $1.81 11/30/202321,580,000 shares $26.54 million +22.7%N/A7.4 $1.23 11/15/202317,590,000 shares $15.13 million -4.5%N/A6.4 $0.86 10/31/202318,410,000 shares $11.73 million -4.9%N/A9.1 $0.64 10/15/202319,360,000 shares $13.99 million -26.5%N/A8.9 $0.72 9/30/202326,330,000 shares $27.12 million +2.3%N/A12.8 $1.03 9/15/202325,750,000 shares $31.16 million +1.7%N/A13.4 $1.21 8/31/202325,320,000 shares $41.52 million -8.8%N/A12.7 $1.64 8/15/202327,760,000 shares $46.50 million +14.2%N/A13.2 $1.68 7/31/202324,310,000 shares $40.35 million +9.4%N/A10.4 $1.66 7/15/202322,220,000 shares $28.22 million -1.0%N/A10.1 $1.27 6/30/202322,440,000 shares $26.03 million -2.0%N/A9.7 $1.16 6/15/202322,890,000 shares $29.99 million -2.1%N/A8.9 $1.31 5/31/202323,380,000 shares $26.65 million +8.0%N/A9 $1.14 5/15/202321,650,000 shares $28.79 million -2.9%N/A8.8 $1.33 4/30/202322,300,000 shares $53.30 million -3.8%N/A10.8 $2.39 4/15/202323,190,000 shares $63.31 million +0.2%N/A10.8 $2.73 3/31/202323,150,000 shares $34.96 million +1.5%N/A10.9 $1.51 3/15/202322,800,000 shares $53.81 million -2.0%N/A12.7 $2.36 2/28/202323,270,000 shares $55.15 million -11.0%N/A10.2 $2.37 2/15/202326,140,000 shares $68.75 million -2.4%N/A11.2 $2.63 1/31/202326,790,000 shares $72.60 million -1.0%N/A10.5 $2.71 1/15/202327,070,000 shares $85.81 million +8.2%N/A10.7 $3.17 12/30/202225,030,000 shares $62.58 million -13.2%N/A9.7 $2.50 12/15/202228,840,000 shares $73.25 million +2.2%N/A10.8 $2.54 11/30/202228,220,000 shares $76.48 million -0.6%N/A10 $2.71 11/15/202228,400,000 shares $90.88 million -1.3%N/A10.1 $3.20 10/31/202228,770,000 shares $110.76 million -1.4%N/A9.3 $3.85 10/15/202229,180,000 shares $107.09 million -12.7%N/A9 $3.67 9/30/202233,420,000 shares $141.03 million +2.1%N/A10.1 $4.22 9/15/202232,720,000 shares $159.35 million +0.2%N/A9.7 $4.87 8/31/202232,650,000 shares $133.54 million -4.0%N/A10.8 $4.09 8/15/202234,000,000 shares $182.58 million -15.9%N/A11.2 $5.37 7/31/202240,430,000 shares $112.40 million +0.6%N/A14.3 $2.78 7/15/202240,180,000 shares $118.13 million +10.3%N/A14.9 $2.94 6/30/202236,440,000 shares $101.67 million -6.5%47.0%13.8 $2.79 6/15/202238,980,000 shares $99.40 million +5.5%50.3%15.5 $2.55 5/31/202236,960,000 shares $121.97 million -0.1%N/A14.6 $3.30 5/15/202236,980,000 shares $132.76 million -0.1%N/A14.4 $3.59 4/30/202237,010,000 shares $167.29 million -0.5%N/A15.7 $4.52 4/15/202237,200,000 shares $218.36 million -5.3%N/A16.2 $5.87 3/31/202239,280,000 shares $224.68 million +16.0%N/A17.1 $5.72 3/15/202233,850,000 shares $163.83 million -2.6%N/A15 $4.84 2/28/202234,750,000 shares $246.73 million -1.4%N/A15.2 $7.10 2/15/202235,240,000 shares $311.52 million +1.7%N/A16.9 $8.84 1/31/202234,640,000 shares $301.71 million -6.3%N/A16.5 $8.71 1/15/202236,960,000 shares $321.55 million +0.9%N/A0 $8.70 12/31/202136,650,000 shares $334.61 million +7.9%N/A18.9 $9.13 12/15/202133,970,000 shares $306.41 million +8.1%N/A17.6 $9.02 11/30/202131,430,000 shares $297.01 million +2.1%N/A18.8 $9.45 11/15/202130,790,000 shares $336.53 million +3.6%N/A21.4 $10.93 10/29/202129,730,000 shares $327.33 million +5.2%N/A21.4 $11.01 10/15/202128,270,000 shares $299.38 million +5.1%N/A21.4 $10.59 9/30/202126,900,000 shares $287.56 million +2.0%N/A20.2 $10.69 9/15/202126,370,000 shares $307.47 million -3.1%N/A21.3 $11.66 8/31/202127,220,000 shares $317.66 million +5.9%N/A21.3 $11.67 8/13/202125,710,000 shares $284.10 million +0.1%N/A17.3 $11.05 7/30/202125,690,000 shares $317.53 million +5.9%N/A14 $12.36 7/15/202124,250,000 shares $317.43 million +2.2%N/A13.9 $13.09 6/30/202123,720,000 shares $368.13 million -1.4%N/A13.8 $15.52 6/15/202124,050,000 shares $372.05 million +1.6%N/A14.5 $15.47 5/28/202123,680,000 shares $314.23 million +11.8%N/A14.5 $13.27 5/14/202121,180,000 shares $329.03 million +0.8%N/A14.3 $15.54 4/30/202121,010,000 shares $370.20 million -1.9%N/A20.4 $17.62 4/15/202121,410,000 shares $369.75 million +1.5%N/A21.2 $17.27 3/31/202121,100,000 shares $322.83 million +2.7%N/A20.9 $15.30 3/15/202120,550,000 shares $348.12 million +2.0%N/A19 $16.94 2/26/202120,150,000 shares $363.71 million +2.2%N/A19.4 $18.05 2/12/202119,710,000 shares $364.83 million +3.0%N/A19.1 $18.51 1/29/202119,140,000 shares $351.41 million +7.8%N/A17.9 $18.36 1/15/202117,760,000 shares $325.72 million +1.3%N/A17.2 $18.34 12/31/202017,530,000 shares $372.86 million -0.4%N/A18.8 $21.27 12/15/202017,600,000 shares $316.10 million -5.2%N/A19.8 $17.96 11/30/202018,560,000 shares $333.89 million +2.5%N/A23 $17.99 11/15/202018,100,000 shares $328.15 million +3.6%N/A23.2 $18.13 10/30/202017,480,000 shares $280.38 million +0.5%N/A24.2 $16.04 10/15/202017,390,000 shares $272.85 million +2.0%N/A23.5 $15.69 HRTX Short Interest - Frequently Asked Questions What is Heron Therapeutics' current short interest? Short interest is the volume of Heron Therapeutics shares that have been sold short but have not yet been covered or closed out. As of September 15th, investors have sold 32,960,000 shares of HRTX short. Learn More on Heron Therapeutics' current short interest. What is a good short interest ratio for Heron Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. HRTX shares currently have a short interest ratio of 19.0. Learn More on Heron Therapeutics's short interest ratio. Which institutional investors are shorting Heron Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Heron Therapeutics: Group One Trading LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Heron Therapeutics' short interest increasing or decreasing? Heron Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 32,960,000 shares, an increase of 1.8% from the previous total of 32,390,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Heron Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Heron Therapeutics: Taysha Gene Therapies, Inc. (15.89%), CorMedix Inc (21.36%), Urogen Pharma (17.16%), Rezolute, Inc. (8.46%), Arbutus Biopharma Corporation (5.82%), Phathom Pharmaceuticals, Inc. (19.73%), Kodiak Sciences Inc. (6.29%), Valneva SE Sponsored ADR (0.02%), Xencor, Inc. (13.45%), Mind Medicine (MindMed) Inc. (14.74%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Corporation ($8.81 billion), Canadian Natural Resources Limited ($5.82 billion), Reddit Inc. ($5.19 billion), Coinbase Global, Inc. ($4.52 billion), Robinhood Markets, Inc. ($4.30 billion), Charter Communications, Inc. ($3.75 billion), CoreWeave Inc. ($3.66 billion), Seagate Technology Holdings PLC ($3.57 billion), Live Nation Entertainment, Inc. ($3.33 billion), and Rocket Lab Corporation ($3.26 billion). View all of the most shorted stocks. What does it mean to sell short Heron Therapeutics stock? Short selling HRTX is an investing strategy that aims to generate trading profit from Heron Therapeutics as its price is falling. HRTX shares are trading up $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Heron Therapeutics? A short squeeze for Heron Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of HRTX, which in turn drives the price of the stock up even further. How often is Heron Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including HRTX, twice per month. The most recent reporting period available is September, 15 2025. More Short Interest Resources from MarketBeat Related Companies Taysha Gene Therapies Short Squeeze CorMedix Short Squeeze Urogen Pharma Short Squeeze Rezolute Short Squeeze Arbutus Biopharma Short Squeeze Phathom Pharmaceuticals Short Squeeze Kodiak Sciences Short Squeeze Valneva Short Squeeze Xencor Short Squeeze Mind Medicine (MindMed) Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:HRTX) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredChina’s New Gold Play Could Make your Income SoarChina's New Gold Move Could Pay You up to $1,152/month. China just announced plans to store other nations' ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
